- Home
- KRMD
KRMD
KORU Medical Systems Inc. (DE)
as 03-28-2025 4:00pm EST
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | MAHWAH |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $4.88 | AVG Volume (30 days): | 170.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.05 - $5.05 | Next Earning Date: | 03-12-2025 |
| Revenue: | $33,646,463 | Revenue Growth: | 17.98% |
| Revenue Growth (this year): | 16.39% | Revenue Growth (next year): | 16.27% |
Latest KORU Medical Systems Inc. (DE) News
KRMD Breaking Stock News: Dive into KRMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
KORU Medical Systems, Inc.'s (NASDAQ:KRMD) market cap dropped US$17m last week; individual investors who hold 43% were hit as were institutions
GuruFocus.com
16 days ago
KORU Medical Systems Inc (KRMD) Q4 2024 Earnings Call Highlights: Record Revenues and Strategic ...
Business Wire
17 days ago
KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance
Business Wire
a month ago
KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
GuruFocus.com
a month ago
Piper Sandler Downgrades Koru Medical, Citing Valuation Concerns
Simply Wall St.
2 months ago
CuriosityStream And 2 Other Promising Penny Stocks On US Exchange
Business Wire
2 months ago
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
Business Wire
2 months ago
KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
Compare KRMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRMD KORU Medical Systems Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.